Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review ; volume:11 ; number:2 ; year:2018 ; pages:527-533
Case reports in oncology ; 11, Heft 2 (2018), 527-533
- Creator
-
Egloff, Heidi
Kidwell, Kelley M.
Schott, Anne
- DOI
-
10.1159/000491574
- URN
-
urn:nbn:de:101:1-2018122623190554966338
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Egloff, Heidi
- Kidwell, Kelley M.
- Schott, Anne
Other Objects (12)
Pulmonary benign metastasising leiomyoma: a single-institution case series
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Clinical and imaging profiles of pulmonary embolism: a single-institution experience
Pulmonary toxicity of polyalkylene glycols
Ado
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Jürgens, Ado (Ado Günther Georg) * 4.11.1867
Robust IMPT and follow-up toxicity in skull base chordoma and chondrosarcoma—a single-institution clinical experience
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Ado, Martyrologium —
Kiess, Ado
Pulmonary benign metastasising leiomyoma: a single-institution case series
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Clinical and imaging profiles of pulmonary embolism: a single-institution experience
Pulmonary toxicity of polyalkylene glycols
Ado
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Jürgens, Ado (Ado Günther Georg) * 4.11.1867
Robust IMPT and follow-up toxicity in skull base chordoma and chondrosarcoma—a single-institution clinical experience
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Ado, Martyrologium —
Kiess, Ado
Pulmonary benign metastasising leiomyoma: a single-institution case series
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Clinical and imaging profiles of pulmonary embolism: a single-institution experience
Pulmonary toxicity of polyalkylene glycols
Ado
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Jürgens, Ado (Ado Günther Georg) * 4.11.1867
Robust IMPT and follow-up toxicity in skull base chordoma and chondrosarcoma—a single-institution clinical experience
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Ado, Martyrologium —